CD38 hat trick

Why Tusk believes its anti-CD38 mAb could be best in class

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates effector T cells.

The CD38 space initially gained prominence based on the speedy development and commercial success of Genmab A/S and Johnson & Johnson’s Darzalex daratumumab in multiple myeloma (MM).

More recently, the target has drawn interest as a possible checkpoint inhibitor

Read the full 763 word article

User Sign In